Showing results (141-150 of 169) with videos related to
Sort By:
Pageof 17
Journal of Acquired Immune Deficiency Syndromes (1999)|July 21, 2021
Urine Cell-Free Mitochondrial DNA as a Marker of Weight Loss and Body Composition in Older Adults With HIVCarrie D Johnston, Eugenia L Siegler, Michelle C Rice, et al.Current Therapeutic Research, Clinical and Experimental|October 30, 2014
Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteersIngrid F Metzger, Troy C Quigg, Noam Epstein, et al.Diagnostic Microbiology and Infectious Disease|August 2, 2022
Cepheid Xpert Xpress Flu/RSV evaluation performed by minimally trained non-laboratory operators in a CLIA-waived environmentBashar S Shihabuddin, Matthew L Faron, Ryan F Relich, et al.The Lancet. HIV|January 15, 2016
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trialSamir K Gupta, Grace A McComsey, John Lombaard, et al.Neurosurgery|January 21, 2021
Laparoscopic-Assisted Versus Mini-Open Laparotomy for Ventriculoperitoneal Shunt Placement in the Medicare PopulationSyed I Khalid, Ravi S Nunna, Samantha Maasarani, et al.Microsystems & Nanoengineering|July 28, 2026
ViraLite: an ultracompact HIV viral load self-testing system with internal quality controlAneesh Kshirsagar, Anthony J Politza, Tianyi Liu, et al.Science Translational Medicine|January 7, 2026
Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defectsNina Pennetzdorfer, Vidula Naik, Sally Demirdjian, et al.Journal of the American Heart Association|June 25, 2021
Depression as a Risk Factor for Incident Ischemic Stroke Among HIV-Positive Veterans in the Veterans Aging Cohort StudyJason J Sico, Suman Kundu, Kaku So-Armah, et al.Hepatology (Baltimore, Md.)|February 22, 2023
Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter studySamer Gawrieh, Jordan E Lake, Paula Debroy, et al.The Lancet. HIV|December 24, 2022
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trialSamir K Gupta, Mezgebe Berhe, Gordon Crofoot, et al.Pageof 17